论文部分内容阅读
对40例脑卒中(包括出血和梗塞)应用小剂量GM_1治疗,并与对照组比较发现,治疗后7d、14d、21d及28GM_1组的临床神经功能缺损评分(CNFDS)显著低于对照组的相应时间,尤其于21d、28d差异更明显。在对急性期和恢复期开始应用GM_1治疗的病例分析发现,GM_1对两者均有理想的治疗效果,急性期应用者可缩短病程;尤其对恢复早期应用者,用药1d即可见效,其CNFDS下降与对照组有显著性差异。说明GM_1是治疗脑卒中很理想的药物,其小剂量即有效,且对恢复早期见效快、疗效好,对其他治疗效果不佳者也可选用。
40 cases of stroke (including bleeding and infarction) with low-dose GM_1 treatment and compared with the control group found that after 7d, 14d, 21d and 28GM_1 clinical neurological deficit score (CNFDS) was significantly lower than the corresponding control group Time, especially at 21d, 28d difference is more obvious. In the acute and convalescent phase of the application of GM_1 case analysis found that, GM_1 have an ideal therapeutic effect on both, acute application of patients can shorten the course of the disease; especially for early recovery of patients, medication 1d can be effective, the CNFDS Decline and the control group have significant differences. Description GM_1 is ideal for the treatment of stroke drug, which is effective in small doses, and early recovery of quick, good effect, for other poor treatment can also be used.